Kinetics of circulating antibody response toTrichomonas vaginalis: clinical and diagnostic implications: Table 1
- 17 April 2015
- journal article
- basic science
- Published by BMJ in Sexually Transmitted Infections
- Vol. 91 (8) , 561-563
Abstract
Objectives Persistence of antibodies against pathogens after antimicrobial treatment is a marker of therapy failure or evolution to a chronic infection. The kinetics of antibody production decrease following antigen elimination is highly variable, and predicting the duration of soluble immunity in infectious diseases is often impossible. This hampers the development and use of immunoassays for diagnostic and seroepidemiological purposes. In the case of Trichomonas vaginalis infection, the kinetics of antibody levels decrease following therapy has never been studied. We thus investigated the clearance of circulating anti-T. vaginalis IgGs after pharmacological treatment in patients affected by trichomoniasis. Methods 18 female patients affected by acute trichomoniasis were enrolled in this study. After metronidazole therapy administration, subjects were followed up monthly up to 5 months, and serum levels of anti-T. vaginalis IgGs were measured by ELISA. Results We showed that a successful therapy is characterised by a relatively fast decline of specific antibodies, until turning into negative by ELISA in 1–3 months. In a few patients we observed that the persistence of anti-T. vaginalis antibodies was associated with an evolution to chronic infection, which may be due to treatment failure or to reinfection by untreated sexual partners. Conclusions Our results describe the direct correlation between the decline of a specific humoral anti-T. vaginalis response and an effective antimicrobial therapy. These findings may facilitate the follow-up approach to circumvent limitations in developing new diagnostic tools and techniques routinely used in microbiology laboratories to assess the presence of T. vaginalis in clinical samples.Keywords
This publication has 11 references indexed in Scilit:
- Trichomonas vaginalis homolog of macrophage migration inhibitory factor induces prostate cell growth, invasiveness, and inflammatory responsesProceedings of the National Academy of Sciences, 2014
- Modern diagnosis ofTrichomonas vaginalisinfectionSexually Transmitted Infections, 2013
- Association ofTrichomonas vaginaliswith its symbiontMycoplasma hominissynergistically upregulates the in vitro proinflammatory response of human monocytesSexually Transmitted Infections, 2013
- APTIMA®Trichomonas vaginalis, a transcription-mediated amplification assay for detection ofTrichomonas vaginalisin urogenital specimensExpert Review of Molecular Diagnostics, 2011
- Rapid detection of coinfections by Trichomonas vaginalis, Mycoplasma hominis, and Ureaplasma urealyticum by a new multiplex polymerase chain reactionDiagnostic Microbiology and Infectious Disease, 2010
- Impact of T. vaginalis infection on innate immune responses and reproductive outcomeJournal of Reproductive Immunology, 2009
- Infection withTrichomonas vaginalisIncreases the Risk of HIV‐1 AcquisitionThe Journal of Infectious Diseases, 2007
- Plasma Antibodies against Trichomonas vaginalis and Subsequent Risk of Prostate CancerCancer Epidemiology, Biomarkers & Prevention, 2006
- Enzyme immunoassay for urogenital trichomoniasis as a marker of unsafe sexual behaviourEpidemiology and Infection, 2001
- Is Trichomonas vaginalis a Cause of Cervical Neoplasia? Results from a Combined Analysis of 24 StudiesInternational Journal of Epidemiology, 1994